Literature DB >> 16409301

P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors.

Gianluca Brusa1, Elisa Zuffa, Manuela Mancini, Michela Benvenuti, Natalia Calonghi, Enza Barbieri, Maria Alessandra Santucci.   

Abstract

The BCR-ABL fusion gene, originating from the balanced (9;22) translocation, is the molecular hallmark and the causative event of chronic myeloid leukaemia (CML). The interactions of its p210 protein constitutively activated and improperly confined to the cytoplasm with multiple regulatory signals of cell cycle progression, apoptosis and self-renewal, induce the illegitimate enlargement of clonal haematopoiesis and genetic instability that drives its progression towards the fully transformed phenotype of blast crisis. However, its effects on the basic transcription machinery and chromatin remodelling are unknown. Our study underscored histone H4 hyperacetylation associated with p210 tyrosine kinase in vitro and in vivo and its role in BCR-ABL transcription. Histone H4 hyperacetylation proceeds, at least partly, from the 'loss of function' of histone deacetylase 1 protein, a critical component of Rb-mediated transcriptional repression, in consequence of its cytoplasmatic compartmentalisation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409301     DOI: 10.1111/j.1365-2141.2005.05873.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.

Authors:  Maria Alessandra Santucci; Manuela Mancini; Valentina Corradi; Ilaria Lacobucci; Giovanni Martinelli; Maurizio Botta; Silvia Schenone
Journal:  Invest New Drugs       Date:  2009-07-24       Impact factor: 3.850

2.  BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks.

Authors:  Rafal Falinski; Margaret Nieborowska-Skorska; Tomasz Skorski
Journal:  Leuk Res       Date:  2011-10-28       Impact factor: 3.156

Review 3.  Epigenetic roots of immunologic disease and new methods for examining chromatin regulatory pathways.

Authors:  Ian A MacDonald; Nathaniel A Hathaway
Journal:  Immunol Cell Biol       Date:  2014-12-23       Impact factor: 5.126

4.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.

Authors:  L Marquard; L M Gjerdrum; Ib J Christensen; P B Jensen; M Sehested; E Ralfkiaer
Journal:  Histopathology       Date:  2008-09       Impact factor: 5.087

5.  Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.

Authors:  Silvia Bono; Matteo Lulli; Vito Giuseppe D'Agostino; Federico Di Gesualdo; Rosa Loffredo; Maria Grazia Cipolleschi; Alessandro Provenzani; Elisabetta Rovida; Persio Dello Sbarba
Journal:  Oncotarget       Date:  2016-12-20

Review 6.  Cancer non-stem cells as a potent regulator of tumor microenvironment: a lesson from chronic myeloid leukemia.

Authors:  Naofumi Mukaida; Yamato Tanabe; Tomohisa Baba
Journal:  Mol Biomed       Date:  2021-03-10

7.  β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation.

Authors:  R Qin; K Li; X Qi; X Zhou; L Wang; P Zhang; L Zou
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.